Insight Molecular Diagnostics (IMDX) Stock Overview
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
IMDX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Insight Molecular Diagnostics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.16 |
| 52 Week High | US$4.75 |
| 52 Week Low | US$1.92 |
| Beta | 0.99 |
| 1 Month Change | 7.48% |
| 3 Month Change | -7.06% |
| 1 Year Change | 10.10% |
| 3 Year Change | -84.51% |
| 5 Year Change | -95.42% |
| Change since IPO | -97.47% |
Recent News & Updates
Recent updates
GraftAssure Assay Submissions Will Unlock Transplant Center Opportunities
Strategic partnerships and anticipated regulatory approvals are poised to significantly expand OncoCyte's market reach, boosting revenue and supporting scalability.Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?
Oct 28
Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test
Aug 30Revisiting OncoCyte Corp.
May 04Shareholder Returns
| IMDX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 17.0% | -2.1% | 0.3% |
| 1Y | 10.1% | -11.0% | 10.4% |
Return vs Industry: IMDX exceeded the US Biotechs industry which returned -9.9% over the past year.
Return vs Market: IMDX matched the US Market which returned 9.9% over the past year.
Price Volatility
| IMDX volatility | |
|---|---|
| IMDX Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 12.2% |
| Market Average Movement | 7.7% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 4.0% |
Stable Share Price: IMDX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: IMDX's weekly volatility (11%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 48 | Josh Riggs | www.oncocyte.com |
OncoCyte Corporation operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.
Insight Molecular Diagnostics Inc. Fundamentals Summary
| IMDX fundamental statistics | |
|---|---|
| Market cap | US$90.37m |
| Earnings (TTM) | -US$58.26m |
| Revenue (TTM) | US$3.84m |
Is IMDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMDX income statement (TTM) | |
|---|---|
| Revenue | US$3.84m |
| Cost of Revenue | US$1.75m |
| Gross Profit | US$2.09m |
| Other Expenses | US$60.36m |
| Earnings | -US$58.26m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.04 |
| Gross Margin | 54.46% |
| Net Profit Margin | -1,516.06% |
| Debt/Equity Ratio | 0% |
How did IMDX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/19 08:03 |
| End of Day Share Price | 2025/06/18 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Insight Molecular Diagnostics Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| Paul Knight | Janney Montgomery Scott LLC |
| null null | KeyBanc Capital Markets Inc. |